|Oculus Innovative Sciences, Inc.|
1129 North McDowell Boulevard
United States - Map
Oculus Innovative Sciences, Inc. designs, produces, and markets prescription and over-the-counter products based on its Microcyn platform technology for the dermatology, surgical, advanced tissue and skin care, and animal healthcare markets in the United States, Mexico, Europe, and internationally. The Microcyn platform technology is based on electrically charged oxychlorine small molecules, which are designed to target a range of pathogens that cause disease, including viruses, fungi, spores, and antibiotic-resistant strains of bacteria, such as methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus, as well as Clostridium difficile, a highly contagious bacteria spread by human contact. It offers Microcyn-based human dermatology and advanced tissue care products as prescription and over-the-counter products; and Microcyn technology-based animal healthcare products under the Vetericyn brand. The companys Microcyn has received ten 510(k) clearances for use as a medical device in wound care management, including for acute and chronic wounds, and in dermatology applications. In addition, it provides consulting and laboratory services to medical companies that design and manufacture biomedical devices and drugs. Oculus Innovative Sciences, Inc. sells its products directly to third parties, and through contract sales organization and distributors to hospitals, physicians, nurses, and other healthcare practitioners, as well as to dermatologists for the treatment of various skin afflictions. Oculus Innovative Sciences, Inc. has a strategic collaborative agreement with the Lipogrid Company of Sweden to develop multiple topical drug delivery formulations. The company was formerly known as Micromed Laboratories, Inc. and changed its name to Oculus Innovative Sciences, Inc. in August 2001. Oculus Innovative Sciences, Inc. was incorporated in 1999 and is headquartered in Petaluma, California.
|Mr. James Schutz ,
Chief Exec. Officer, Pres and Director
|Mr. Robert E. Miller ,
Chief Operating Officer, Chief Financial Officer, Principal Accounting Officer and Corp. Sec.
|Mr. Bruce Thornton ,
Exec. VP of International Operations & Sales
|Mr. Robert Northey Ph.D.,
Exec. VP of R&D
|Mr. Dan McFadden ,
Director of Public & Investor Relations
|Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|